Skip to content

Xeris Biopharma Holdings, Inc. XERS Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Corcept Therapeutics logo
Corcept TherapeuticsCORT
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
BridgeBio Pharma logo
BridgeBio PharmaBBIO
LQD
Liquidia CorporationLQDA

Other financials

Income statement

See full
Revenue$83.1M+38.3%
Gross profit$72.6M+41.2%
Operating income$7.9M+356%
Net income$2.2M+124%
EPS (diluted)$0.01+117%

Balance sheet

See full
Cash & equivalents$111.8M+91.2%
Total debt$258.6M-3.8%
Total equity$13.0M+137%
Total assets$392.0M+24.3%

Cash flow

See full
Operating cash flow$9.9M+198%
CapEx$131.0K
Free cash flow-$29.1M

Valuation

See full
Market cap$1.28B+18.3%
Enterprise value$1.42B+8.7%
P/E106.4×
P/S4.1×-0.8×

Profitability

See full
Gross margin85.9%+3.7pp
Operating margin11.4%+7.7pp
Net margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-209.8%
Debt / equity19.9×
Current ratio2.1×+0.4×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s operating lease right-of-use assets in other assets?
Xeris Biopharma Holdings, Inc. (XERS) reported operating lease right-of-use assets in other assets of $21.95M in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
Xeris Biopharma Holdings, Inc.'s operating lease right-of-use assets in other assets decreased by 2.6% year-over-year, from $22.53M to $21.95M.